- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05046860
Efficacy of Dalbavancin in Osteoarticular Infections Associated With Hip and Knee Replacements (PRODALBA)
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Johan COURJON, MD
- Phone Number: +33 0492035452
- Email: courjon.j@chu-nice.fr
Study Locations
-
-
-
Boulogne-Billancourt, France, 92100
- Recruiting
- AP-HP - Hôpital Ambroise-Paré
-
Contact:
- Aurélien DINH
- Email: aurelien.dinh@aphp.fr
-
Nice, France
- Recruiting
- CHU de Nice
-
Contact:
- Johan Courjon, MD
-
Tourcoing, France, 59208
- Recruiting
- Centre Hospitalier de Tourcoing
-
Contact:
- Eric SENNEVILLE
-
Contact:
- Email: esenneville@ch-tourcoing.fr
-
Tours, France, 37000
- Recruiting
- CHRU de Tours
-
Contact:
- Adrien LEMAIGNEN
- Email: adrien.lemaignen@univ-tours.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age greater than or equal to 18 years
- First monomicrobial osteoarticular infection of knee or hip prosthesis with staphylococcus sensitive to dalbavancin (determined by a minimum inhibitory concentration by microdilution of the strain in question for vancomycin less than or equal to 2mg/L) and rifampicin, treated surgically by debridement, antibiotics and implant retention with change of moving parts (acute infections) or change in 1 stage (chronic infections)
- Social security affiliation
- Signature of informed consent
Exclusion Criteria:
- Hypersensitivity to glycopeptides or rifampin or to any of the excipients
- Porphyrias
- Probabilistic antibiotic treatment not administered within 24 hours of surgery
- Probabilistic antibiotic treatment that did not take into account the bacterium causing the infection in its spectrum
- Acute hematogenous infection (acute secondary)
- Use of background treatment incompatible with the inducing effect of rifampicin (see Summary of Product Characteristics for rifampicin)
- Contraindications to rifampin therapy: Moderate to severe impairment of liver function, patients with a history of hypersensitivity to other rifamycins, porphyria.
Hepatic cirrhosis
- Use of ototoxic therapy, such as an aminoglycoside
- Renal function with glomerular filtration rate less than 30 ml/min as measured by MDRD (Modification of Diet in Renal Disease)
- Pregnant and breastfeeding women: at inclusion a blood pregnancy test will be performed for women of childbearing age. The results will be communicated to the patient by a physician of her choice.
- Women of childbearing age not using an effective method of contraception (pill, intrauterine device, vaginal ring, contraceptive skin patch, hormonal subcutaneous implant, surgical sterilization)
- Protected persons defined in the following articles of the public health code:
L. 1121-6: persons deprived of liberty by a judicial or administrative decision, persons hospitalized without consent and persons admitted to a health or social establishment for purposes other than research; L. 1121-8: adults subject to a legal protection measure or unable to express their consent; L. 1122-1-2: persons in emergency situations who are unable to give prior consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dalbavancine + Rifampicine
|
The unit dose of dalbavancin administered via the peripheral venous route will be 1500 mg at each injection with a first injection at Day1, a second injection at Day15 and a third at Day36, which corresponds to 61 days of treatment with dalbavancin. In case of residual dalbavancin dosage at Day15 lower than 15 mg/L (rare situation) and a minimal inhibitory concentration for dalbavancin of 0.125mg/L (less than 5% of the strains), an injection every 14 days will be necessary, i.e. Day1, Day15, Day29, Day43 and Day57, which corresponds to 71 days of dalbavancin treatment. Rifampicin should be given orally at a dose of 600 mg on an empty stomach in the morning for patients weighing less than 70 kg and 900 mg on an empty stomach in the morning for patients weighing more than 70 kg. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
therapeutic success
Time Frame: 12 months
|
therapeutic success defined by the absence of failure within 12 months of surgical management
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
therapeutic success at 24 months
Time Frame: 24 months
|
therapeutic success defined by the absence of failure within 24 months of surgical management
|
24 months
|
Tolerance
Time Frame: 6 months of first administration of dalbavancin
|
Tolerance will be assessed by collecting adverse events during treatment with dalbavancin and rifampin classified according to Common Terminology Criteria for Adverse Events (version 5.0) within 6 months of its first administration.
|
6 months of first administration of dalbavancin
|
Residual dalbavancin dosage
Time Frame: Day 61 of first administration of dalbavancin
|
Residual dalbavancin dosage at Day61
|
Day 61 of first administration of dalbavancin
|
Collaborators and Investigators
Investigators
- Principal Investigator: Aurélien DINH, MD, AP-HP - Hôpital Ambroise-Paré
- Principal Investigator: Eric SENNEVILLE, PD, Centre Hospitalier de Tourcoing
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-AOI-03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarticular Infection
-
Rennes University HospitalCompletedOsteoarticular InfectionFrance
-
Assistance Publique - Hôpitaux de ParisCompletedOsteoarticular InfectionFrance
-
Centre Hospitalier Universitaire, AmiensCompletedOsteoarticular InfectionFrance
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
University Hospital, MontpellierCompleted
-
Assistance Publique - Hôpitaux de ParisCompletedBone and Osteoarticular Infection Due to MDR M. Tuberculosis StrainsFrance
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Ahmad Jabir RahyussalimUnknownMesenchymal Stem Cell | Spinal TuberculosisIndonesia
-
University of Cape TownUniversity of ZurichRecruitingInfections | Musculoskeletal Diseases | Mycobacterium Infections | Tuberculosis | Spondylitis | Bone Diseases, Infectious | Diagnostic Imaging | Positron-Emission Tomography | Spondylodiscitis | Spinal Disease | Tuberculosis, Spinal | Tuberculosis, Osteoarticular | Diagnostic Techniques and Procedures | Spondylitis...South Africa
-
Beijing Chest HospitalBeijing Municipal Science & Technology CommissionUnknownTuberculosis, SpinalChina
Clinical Trials on Dalbavancin
-
AbbVieCompletedBacterial Infections | Staphylococcal Skin Infections | Methicillin-Resistant Staphylococcus AureusUnited States, Bulgaria, Chile, Colombia, Georgia, Greece, Guatemala, Latvia, Mexico, Panama, Spain, Ukraine
-
University of Colorado, DenverCompletedInfectious PeritonitisUnited States
-
Vicuron PharmaceuticalsUnknown
-
Tourcoing HospitalCompletedProsthesis-related InfectionsFrance
-
Durata Therapeutics Inc., an affiliate of Allergan...CompletedAbscess | Cellulitis | Surgical Site Infection | Wound InfectionUnited States, Bulgaria, Croatia, Estonia, Georgia, Hungary, Latvia, Romania, Russian Federation, Serbia, South Africa, Ukraine
-
Assistance Publique - Hôpitaux de ParisAdvanz Pharma; Centre Hospitalier de Perigueux; CHU de Nantes; Centre National...RecruitingStaphylococcus Aureus Infection | Catheter BacteremiaFrance
-
Durata Therapeutics Inc., an affiliate of Allergan...CompletedAbscess | Cellulitis | Surgical Site Infection | Wound InfectionUnited States, Bulgaria, Estonia, Hungary, Israel, Korea, Republic of, Latvia, Lithuania, Romania, Russian Federation, Slovakia, South Africa, Taiwan, Ukraine
-
Durata Therapeutics Inc., an affiliate of Allergan...CompletedBacterial Infections.United States, Estonia
-
Correvio International SarlPrimeVigilance; AMS Advanced Medical Services GmbHTerminated
-
PfizerCompletedBacterial InfectionsUnited States